Al-Saraireh Y, Alshammari F, Abu-Azzam O, Al-Dalain S, Al-Sarayra Y, Haddad M
Biomedicines. 2023; 11(11).
PMID: 38001897
PMC: 10669316.
DOI: 10.3390/biomedicines11112898.
Molina-Ortiz D, Torres-Zarate C, Santes-Palacios R
Curr Drug Metab. 2022; 23(12):942-963.
PMID: 36503398
DOI: 10.2174/1389200224666221209153032.
Han J, Yee J, Chung J, Lee K, Park K, Gwak H
Mol Genet Genomic Med. 2020; 8(5):e1201.
PMID: 32134573
PMC: 7216797.
DOI: 10.1002/mgg3.1201.
Matsumoto J, San S, Fujiyoshi M, Kawauchi A, Chiba N, Tagai R
J Hum Genet. 2019; 65(2):143-153.
PMID: 31645655
DOI: 10.1038/s10038-019-0685-2.
Li H, Lampe J
Arch Biochem Biophys. 2019; 673:108078.
PMID: 31445893
PMC: 6739124.
DOI: 10.1016/j.abb.2019.108078.
Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?.
Prytula A, Cransberg K, Raes A
Pediatr Nephrol. 2018; 34(7):1201-1210.
PMID: 30058048
DOI: 10.1007/s00467-018-4030-3.
Ancestry-Adjusted Vitamin D Metabolite Concentrations in Association With Cytochrome P450 3A Polymorphisms.
Wilson R, Masters L, Barnholtz-Sloan J, Salzberg A, Hartman T
Am J Epidemiol. 2017; 187(4):754-766.
PMID: 28673024
PMC: 5888975.
DOI: 10.1093/aje/kwx187.
Effects of maternal acrolein exposure during pregnancy on testicular testosterone production in fetal rats.
Yang Y, Zhang Z, Zhang H, Hong K, Tang W, Zhao L
Mol Med Rep. 2017; 16(1):491-498.
PMID: 28560422
PMC: 5482093.
DOI: 10.3892/mmr.2017.6624.
Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.
Lolodi O, Wang Y, Wright W, Chen T
Curr Drug Metab. 2017; 18(12):1095-1105.
PMID: 28558634
PMC: 5709240.
DOI: 10.2174/1389200218666170531112038.
Genetic variation in CYP3A43 is associated with response to antipsychotic medication.
Brandl E, Chowdhury N, Tiwari A, Lett T, Meltzer H, Kennedy J
J Neural Transm (Vienna). 2014; 122(1):29-34.
PMID: 25150845
DOI: 10.1007/s00702-014-1298-8.
The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.
Michaels S, Wang M
Drug Metab Dispos. 2014; 42(8):1241-51.
PMID: 24816681
PMC: 4109210.
DOI: 10.1124/dmd.114.058040.
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
Wang D, Sadee W
J Pers Med. 2014; 2(4):175-91.
PMID: 24466438
PMC: 3901424.
DOI: 10.3390/jpm2040175.
Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.
Ince I, Knibbe C, Danhof M, de Wildt S
Clin Pharmacokinet. 2013; 52(5):333-45.
PMID: 23463352
DOI: 10.1007/s40262-013-0041-1.
Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
Moore C, Roberts J, Orton C, Murai T, Fidler T, Reilly C
Drug Metab Dispos. 2012; 41(2):379-89.
PMID: 23143891
PMC: 3558858.
DOI: 10.1124/dmd.112.046318.
Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology.
Guengerich F, Cheng Q
Pharmacol Rev. 2011; 63(3):684-99.
PMID: 21737533
PMC: 3141877.
DOI: 10.1124/pr.110.003525.
Integrated transcriptional and proteomic analysis with in vitro biochemical assay reveal the important role of CYP3A46 in T-2 toxin hydroxylation in porcine primary hepatocytes.
Wang J, Jiang J, Zhang H, Wang J, Cai H, Li C
Mol Cell Proteomics. 2011; 10(9):M111.008748.
PMID: 21685020
PMC: 3186201.
DOI: 10.1074/mcp.M111.008748.
The cyclophosphamide metabolite, acrolein, induces cytoskeletal changes and oxidative stress in Sertoli cells.
Liu F, Li X, Lin T, He D, Wei G, Liu J
Mol Biol Rep. 2011; 39(1):493-500.
PMID: 21553225
DOI: 10.1007/s11033-011-0763-9.
Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.
Bigos K, Bies R, Pollock B, Lowy J, Zhang F, Weinberger D
Mol Psychiatry. 2011; 16(6):620-5.
PMID: 21519338
PMC: 3100476.
DOI: 10.1038/mp.2011.38.
Decision tree-based modeling of androgen pathway genes and prostate cancer risk.
Barnholtz-Sloan J, Guan X, Zeigler-Johnson C, Meropol N, Rebbeck T
Cancer Epidemiol Biomarkers Prev. 2011; 20(6):1146-55.
PMID: 21493872
PMC: 3111844.
DOI: 10.1158/1055-9965.EPI-10-0996.
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman S, Ma Q, Morse G
Pharmacogenomics. 2009; 10(8):1323-39.
PMID: 19663676
PMC: 2776626.
DOI: 10.2217/pgs.09.53.